• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular Complications in Coronavirus Disease 2019-Pathogenesis and Management
Semin Respir Crit Care Med. 2023 Feb;44(1):21-34. doi: 10.1055/s-0042-1760096. Epub 2023 Jan 16.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has caused a devastating impact on morbidity and mortality around the world. Severe acute respiratory syndrome-coronavirus-2 has a characteristic tropism for the cardiovascular system by entering the host cells and binding to angiotensin-converting enzyme 2 receptors, which are expressed in different cells, particularly endothelial cells. This endothelial injury is linked by a direct intracellular viral invasion leading to inflammation, microthrombosis, and angiogenesis. C...
Source: Respiratory Care - January 16, 2023 Category: Respiratory Medicine Authors: Marcos I Restrepo Judith Marin-Corral Juan J Rodriguez Valeria Restrepo Rodrigo Cavallazzi Source Type: research

Cardiovascular Complications in Coronavirus Disease 2019 —Pathogenesis and Management
Semin Respir Crit Care Med 2023; 44: 021-034 DOI: 10.1055/s-0042-1760096The coronavirus disease 2019 (COVID-19) pandemic has caused a devastating impact on morbidity and mortality around the world. Severe acute respiratory syndrome-coronavirus-2 has a characteristic tropism for the cardiovascular system by entering the host cells and binding to angiotensin-converting enzyme 2 receptors, which are expressed in different cells, particularly endothelial cells. This endothelial injury is linked by a direct intracellular viral invasion leading to inflammation, microthrombosis, and angiogenesis. COVID-19 has been associated with...
Source: Seminars in Respiratory and Critical Care Medicine - January 16, 2023 Category: Respiratory Medicine Authors: Restrepo, Marcos I. Marin-Corral, Judith Rodriguez, Juan J. Restrepo, Valeria Cavallazzi, Rodrigo Tags: Review Article Source Type: research

A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS).
Conclusion: The GARDEN study was set up to tackle a global Public Health emergency. Glenzocimab was safe in doses three times higher than used in stroke. Albeit efficacy was not shown, overall, GARDEN provides insights into Cov-ARDS.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Pottecher, J., Sato, V. A. H., Pletan, Y., Comenducci, A., Desort-Henin, V., Jandrot-Perrus, M., Binay, S., Meilhoc, A., Avenard, G. Tags: 02.01 - Acute critical care Source Type: research

Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
Eur Respir Rev. 2022 Nov 2;31(166):220098. doi: 10.1183/16000617.0098-2022. Print 2022 Dec 31.ABSTRACTBACKGROUND: As mortality from coronavirus disease 2019 (COVID-19) is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age-/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations.METHODS: We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to sever...
Source: Respiratory Care - November 2, 2022 Category: Respiratory Medicine Authors: Constantine I Vardavas Alexander G Mathioudakis Katerina Nikitara Kimon Stamatelopoulos Georgios Georgiopoulos Revati Phalkey Jo Leonardi-Bee Esteve Fernandez Dolors Carnicer-Pont J ørgen Vestbo Jan C Semenza Charlotte Deogan Jonathan E Suk Piotr Kramarz Source Type: research

Controversies over the impact of the COVID-19 pandemic on patients with Pulmonary Arterial Hypertension
This study is a retrospective analysis of our PAH patients treated in 2020 compared to the dynamics of the last 12 years. We had 48 PAH patients, 51.72±16.64 years, 72.91% female. All patients had chronic anticoagulant therapy(58.33%) and/or antiplatelet; 33.33% had long term oxygen therapy. Three patients with secondary forms were confirmed with COVID-19, all hospitalized (6.25% infection rate versus 3.29% in general). One patient died(75 years with scleroderma, stroke), two patients were cured (mild forms). In total only three patients died in 2020. Surprisingly, compared with 2008-2019 (101 patients/ 41 deaths, 3...
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Bertici, N. S., Dobrescu, L., Pislaru, L., Marincu, I. Tags: Pulmonary hypertension Source Type: research

STudy of Alteplase for Respiratory failure in SARS-Cov2 COVID-19 (STARS): A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized, Controlled Trial
Chest. 2021 Sep 27:S0012-3692(21)04063-0. doi: 10.1016/j.chest.2021.09.024. Online ahead of print.ABSTRACTBACKGROUND: Pulmonary vascular microthrombi are a proposed mechanism of COVID19 respiratory failure. We hypothesized that early administration of tissue-plasminogen activator(tPA) followed by therapeutic heparin would improve pulmonary function in these patients.RESEARCH QUESTION: Does tPA improve pulmonary function in severe COVID-19 respiratory failure, and is it safe?STUDY DESIGN AND METHODS: Adults with COVID-19-induced respiratory failure were randomized May14,2020-March 3,2021 in two phases: Phase-1(n=36): contro...
Source: Chest - September 30, 2021 Category: Respiratory Medicine Authors: Christopher D Barrett Hunter B Moore Ernest E Moore D Janice Wang Negin Hajizadeh Walter L Biffl Lawrence Lottenberg Purvesh R Patel Michael S Truitt Robert McIntyre Todd M Bull Lee Anne Ammons Arsen Ghasabyan James Chandler Ivor Douglas Eric Schmidt Pete Source Type: research

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Lancet Respir Med. 2021 Jul 27:S2213-2600(21)00310-6. doi: 10.1016/S2213-2600(21)00310-6. Online ahead of print.ABSTRACTBACKGROUND: Doxycycline is often used for treating COVID-19 respiratory symptoms in the community despite an absence of evidence from clinical trials to support its use. We aimed to assess the efficacy of doxycycline to treat suspected COVID-19 in the community among people at high risk of adverse outcomes.METHODS: We did a national, open-label, multi-arm, adaptive platform randomised trial of interventions against COVID-19 in older people (PRINCIPLE) across primary care centres in the UK. We included peo...
Source: Respiratory Care - July 30, 2021 Category: Respiratory Medicine Authors: Christopher C Butler Ly-Mee Yu Jienchi Dorward Oghenekome Gbinigie Gail Hayward Benjamin R Saville Oliver Van Hecke Nicholas Berry Michelle A Detry Christina Saunders Mark Fitzgerald Victoria Harris Ratko Djukanovic Stephan Gadola John Kirkpatrick Simon d Source Type: research

Pulmonary Endothelial Dysfunction and Thrombotic Complications in COVID-19 Patients.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). PMID: 33180562 [PubMed - as supplied by publisher]
Source: Am J Respir Cell Mol... - November 12, 2020 Category: Respiratory Medicine Authors: Rodríguez C, Luque N, Blanco I, Sebastian L, Barberà JA, Peinado VI, Tura-Ceide O Tags: Am J Respir Cell Mol Biol Source Type: research